Mechanism underlying the role of the circRNA OMA1/miR-654-3p/RAF1 axis in children with inflammatory bowel disease
- PMID: 39867828
- PMCID: PMC11759725
- DOI: 10.1007/s10616-025-00703-z
Mechanism underlying the role of the circRNA OMA1/miR-654-3p/RAF1 axis in children with inflammatory bowel disease
Erratum in
-
Correction: Mechanism underlying the role of the circRNA OMA1/miR-654-3p/RAF1 axis in children with inflammatory bowel disease.Cytotechnology. 2025 Jun;77(3):109. doi: 10.1007/s10616-025-00770-2. Epub 2025 May 28. Cytotechnology. 2025. PMID: 40453924 Free PMC article.
Abstract
Inflammatory bowel disease (IBD), a chronic gastrointestinal disorder, often emerges during childhood and poses significant challenges due to its adverse effects on growth, development, and psychosocial well-being. Circular RNAs (circRNAs) have been implicated in the pathogenesis of diverse diseases. However, the specific biological role and mechanisms of circRNA OMA1 in children with IBD remain largely unexplored. This study investigates the functions and mechanistic pathways of circRNA OMA1 in the progression of IBD. Quantitative real-time PCR (qRT-PCR) was employed to quantify circRNA OMA1 and miR-654-3p expression levels in the serum of children with IBD and in HT-29 cells. Downstream miRNA and mRNA targets of circRNA OMA1 were predicted using StarBase and validated via luciferase reporter assays. An in vitro IBD model was established by treating the human colonic epithelial cell line (HT-29) with 2% dextran sulfate sodium (DSS). Cell viability and apoptosis were assessed using the MTT assay and flow cytometry, respectively. Expression of the apoptosis-related protein cleaved caspase-3 was analyzed via western blotting, and proinflammatory cytokine levels (TNF-α, IL-1β, and IL-6) were measured using ELISA. The expression of circRNA OMA1 was notably lower in the serum of children with IBD and in DSS-treated HT-29 cells than in healthy controls, whereas miR-654-3p expression was upregulated. Bioinformatics analyses revealed a direct interaction between circRNA OMA1 and miR-654-3p. Overexpression of circRNA OMA1 through plasmid transfection increased circRNA OMA1 levels and suppressed miR-654-3p expression in HT-29 cells under both basal and DSS-stimulated conditions. Conversely, transfection with a miR-654-3p mimic reversed these effects. Upregulation of circRNA OMA1 ameliorated DSS-induced injury in HT-29 cells by enhancing cell viability, reducing apoptosis, and downregulating cleaved caspase-3 expression. Moreover, circRNA OMA1 overexpression inhibited the secretion of inflammatory cytokines TNF-α, IL-1β, and IL-6. However, these protective effects were partially reversed by treatment with the miR-654-3p mimic. Additionally, miR-654-3p was shown to directly target RAF1, negatively regulating its expression. The proliferation-promoting and apoptosis-suppressing effects of miR-654-3p inhibitor treatment were mitigated by RAF1-siRNA. Conclusion: Upregulation of circRNA OMA1 alleviates DSS-induced colonic cell apoptosis and inflammation by modulating the miR-654-3p/RAF1 axis. These findings suggest that circRNA OMA1 could be a promising biomarker for the diagnosis and treatment of IBD.
Supplementary information: The online version contains supplementary material available at 10.1007/s10616-025-00703-z.
Keywords: Children with inflammatory bowel disease; circRNA OMA1; miR-654-3p/RAF1 axis.
© The Author(s), under exclusive licence to Springer Nature B.V. 2025. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Conflict of interest statement
Conflict of interestThe authors declare that they have no competing interests.
Similar articles
-
Expression and role of CTHRC1 in inflammatory bowel disease in children.Cytotechnology. 2025 Apr;77(2):44. doi: 10.1007/s10616-025-00705-x. Epub 2025 Jan 25. Cytotechnology. 2025. PMID: 39867826
-
Circular RNA NFIX Functions as an Oncogene in Non-Small Cell Lung Cancer by Modulating the miR-214-3p/TRIAP1 Axis.Clin Respir J. 2024 Aug;18(8):e13801. doi: 10.1111/crj.13801. Clin Respir J. 2024. PMID: 39135128 Free PMC article.
-
Circ-IGF1R plays a significant role in psoriasis via regulation of a miR-194-5p/CDK1 axis.Cytotechnology. 2021 Dec;73(6):775-785. doi: 10.1007/s10616-021-00496-x. Epub 2021 Sep 30. Cytotechnology. 2021. PMID: 34776628 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
Cited by
-
MicroRNAs as Key Modulators of Intestinal Barrier Function: Pattern Recognition Receptors, Epithelial Junctional Complexes, and Therapeutic Approaches.Dig Dis Sci. 2025 Jun 21. doi: 10.1007/s10620-025-09131-7. Online ahead of print. Dig Dis Sci. 2025. PMID: 40544176 Review.
References
-
- Bisgaard TH, Allin KH, Keefer L, Ananthakrishnan AN, Jess T (2022) Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment. Nat Rev Gastroenterol Hepatol 19:717–726. 10.1038/s41575-022-00634-6 - PubMed
-
- Bruner LP, White AM, Proksell S (2023) Inflammatory bowel disease. Prim Care 50:411–427. 10.1016/j.pop.2023.03.009 - PubMed
-
- Federici S, Kredo-Russo S, Valdes-Mas R et al (2022) Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell 185:2879-2898.e24. 10.1016/j.cell.2022.07.003 - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous